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Abstract: BACKGROUND Severe coronavirus disease 2019 (COVID-19) frequently entails complications
that bear similarities to autoimmune diseases. To date, there is little data on possible IgA-mediated au-
toimmune responses. Here, we aim to determine whether COVID-19 is associated with a vigorous total
IgA response and if IgA antibodies are associated with complications of severe illness. Since thrombotic
events are frequent in severe COVID-19 and resemble hypercoagulation of antiphospholipid syndrome
(APS), our approach focused on antiphospholipid antibodies (aPL). METHODS In this retrospective co-
hort study clinical data and aPL from 64 patients with COVID-19 were compared from three independent
tertiary hospitals (one in Liechtenstein, two in Switzerland). Samples were collected from April 9 th to
May 1 st, 2020. RESULTS Clinical records of 64 patients with COVID-19 were reviewed and divided into
a cohort with mild illness (mCOVID) (41%), a discovery cohort with severe illness (sdCOVID) (22%) and
a confirmation cohort with severe illness (scCOVID) (38%). Total IgA, IgG and aPL were measured with
clinical diagnostic kits. Severe illness was significantly associated with increased total IgA (sdCOVID,
P=0.01; scCOVID, p-value<0.001), but not total IgG. Among aPL, both cohorts with severe illness
significantly correlated with elevated anti-Cardiolipin IgA (sdCOVID and scCOVID, p-value<0.001),
anti-Cardiolipin IgM (sdCOVID, P=0.003; scCOVID, P<0.001), and anti-Beta2 Glycoprotein-1 IgA (sd-
COVID and scCOVID, P<0.001). Systemic lupus erythematosus was excluded from all patients as a
potential confounder. CONCLUSIONS Higher total IgA and IgA-aPL were consistently associated with
severe illness. These novel data strongly suggest that a vigorous antiviral IgA-response, possibly triggered
in the bronchial mucosa, induces systemic autoimmunity.
DOI: https://doi.org/10.1093/cid/ciaa1496
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Our retrospective cohort study in Liechtenstein and Switzerland found that severe COVID-19 
is significantly associated with elevated total IgA and IgA antiphospholipid antibodies. These 
data suggest that a vigorous IgA response to SARS-CoV-2 may trigger autoimmunity with 













Background: Severe coronavirus disease 2019 (COVID-19) frequently entails complications 
that bear similarities to autoimmune diseases. To date, there is little data on possible IgA-
mediated autoimmune responses. Here, we aim to determine whether COVID-19 is 
associated with a vigorous total IgA response and if IgA antibodies are associated with 
complications of severe illness. Since thrombotic events are frequent in severe COVID-19 
and resemble hypercoagulation of antiphospholipid syndrome (APS), our approach focused 
on antiphospholipid antibodies (aPL). 
 
Methods: In this retrospective cohort study clinical data and aPL from 64 patients with 
COVID-19 were compared from three independent tertiary hospitals (one in Liechtenstein, 
two in Switzerland). Samples were collected from April 9th to May 1st, 2020. 
 
Results: Clinical records of 64 patients with COVID-19 were reviewed and divided into a 
cohort with mild illness (mCOVID) (41%), a discovery cohort with severe illness (sdCOVID) 
(22%) and a confirmation cohort with severe illness (scCOVID) (38%). Total IgA, IgG and 
aPL were measured with clinical diagnostic kits. Severe illness was significantly associated 
with increased total IgA (sdCOVID, P=0.01; scCOVID, p-value<0.001), but not total IgG. 
Among aPL, both cohorts with severe illness significantly correlated with elevated anti-
Cardiolipin IgA (sdCOVID and scCOVID, p-value<0.001), anti-Cardiolipin IgM (sdCOVID, 
P=0.003; scCOVID, P<0.001), and anti-Beta2 Glycoprotein-1 IgA (sdCOVID and scCOVID, 













Conclusions: Higher total IgA and IgA-aPL were consistently associated with severe illness. 
These novel data strongly suggest that a vigorous antiviral IgA-response, possibly triggered 
in the bronchial mucosa, induces systemic autoimmunity. 
 














The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic with wide-
ranging health and socio-economic implications. After SARS and the Middle East 
Respiratory Syndrome, it represents the third known spillover of a severe 
coronavirus-associated disease from animals to humans in the last twenty years [1-
3]. SARS-CoV-2 enters human cells by attachment to and subsequent internalization 
of Angiotensin-converting enzyme 2 receptors that are highly expressed by type-II 
pneumocytes in the deep bronchial system [4], where IgA immunoglobulins 
produced in the bronchial-associated lymphoid tissue (BALT) are the main line of 
humoral defense [5]. Indeed, specific IgA against the SARS-CoV-2 spike protein 
have been shown to appear early in infected patients [6]. However, despite the 
important role of IgA in mucosal immunity, the rate of total IgA generated by that 
response and its role in COVID-19 severity remains unexplored. 
Autopsies have shown acute respiratory distress syndrome (ARDS) and sepsis to be 
the most common complications in critically-ill COVID-19 patients [7]. A large case 
series from Northern Italy that assessed lung histologies of deceased COVID-19 
patients present consistent diffuse alveolar damage and necrosis of pneumocytes 
[8]. A distinctive factor for COVID-19 was a marked presence of diffuse thrombosis 
of the peripheral small vessels. This is in line with reports of frequent 
thromboembolisms of patients with severe COVID-19 that occur despite the 
prophylactic in-hospital use of low weight molecular heparins [9, 10]. While the 
reasons remain unclear, a recent report describes a case series of severe COVID-19 
patients with stroke and elevated levels of antiphospholipid (aPL) antibodies 











autoimmune disease that is mediated by autoantibodies directed against 
phospholipid-binding proteins that leads to hypercoagulability. The most common 
trigger factor of APS is systemic lupus erythematosus (SLE), followed by lung 
infections with mycobacteria or viruses [12]. These cases suggest that COVID-19 
leads to virally triggered APS in severe COVID-19 patients. To our knowledge, 
complete aPL profiling in mild and severe cases of COVID-19 has never been 
undertaken. The aim of this study was to explore, whether patients with severe 
COVID-19 have elevated total IgA as an immediate immune response and aPL 
compatible with APS. 
 
METHODS 
Sources and Ethical Statement: 
The multicenter cohort study was conducted at the Landesspital Liechtenstein (LLS) in 
Vaduz, Liechtenstein, the Kantonsspital St. Gallen (KSSG) in St. Gallen, Switzerland, and 
the University Hospital Zurich (USZ) in Zurich, Switzerland, in accordance with the 
Declaration of Helsinki guidelines. The collection of patient data and blood samples was 
approved by the respective local ethics committees of the participating study centers 
(Project-IDs 2020-00676, 2020-00821, and 2020-00646). All participants agreed to the 
hospitals’ general consent policies allowing further use of clinical data and biologic material 
(LLS and KSSG) or signed an informed consent (USZ). Where signing of informed consent 
was not possible due to severe illness and to prevent surface contamination, consent was 














Patient data and sample collection: 
Collection of patient data and samples (serum or plasma) was conducted from April 9, 2020, 
to May 1, 2020. All samples were obtained within two weeks of symptom onset. Patients with 
SARS-CoV-2 infection were included that had been confirmed by either real-time reverse 
transcriptase-polymerase chain reaction (RT-PCR) of nasopharyngeal swab samples or 
serology. The methods of RT-PCR used to detect SARS-CoV-2 depended on the study 
center and were performed as previously described [13, 14]. For confirmation with serology 
SARS-CoV-2 antibodies were analyzed by two independent antibody tests: a lateral flow 
immunochromatographic assay (LFIA, gold nanoparticle-based, SGIT flex Covid 19) 
(Sugentech, Daejeon, South Korea) and an electro-chemiluminescence immunoassay 
(ECLIA, Elecsys Anti-SARS-CoV-2) (Roche International Diagnostics AG, Rotkreuz, 
Switzerland). Seropositivity was defined as a positive IgM signal in the LFIA in the acute 
phase that was confirmed by IgG in the ECLIA after 3-4 weeks.  
Patients were categorized into the following cohorts: 1. mild illness without requirement of 
hospitalization (mCOVID) which were collected at the LLS, 2. a discovery cohort of patients 
with severe illness (sdCOVID) obtained at the USZ, and 3. an independent confirmation 
cohort of patients with severe illness (scCOVID) from the KSSG. Mild illness was defined as 
uncomplicated upper respiratory tract infection with unspecific symptoms or uncomplicated 
pneumonia, while severe illness for the sdCOVID and scCOVID cohorts required 
hospitalization and included severe pneumonia, ARDS, and septic shock [15].  
 
Immunoglobulins and aPL testing: 
aPL antibodies were determined by fluorescence enzyme immunoassay on a Phadia 250 
analyzer (Thermo Fisher Diagnostics AG, Steinhausen, Switzerland) using EliATM 
Cardiolipin as well as EliATM Beta 2-Glycoprotein 1 assays for IgG, IgA, and IgM isotoypes 











determined on a Cobas c501 analyzer (Roche International Diagnostics AG, Rotkreuz, 
Switzerland) with a nephelometric assay (IgA-2, Tina-quant IgA Gen.2, and IgGu2, Tina-
quant IgG Gen.2) (Roche International Diagnostics AG, Rotkreuz, Switzerland). IgG against 
SS-A/Ro, SS-B/La, dsDNA, Sm, chromatin and RNP were simultaneously determined by 
bead-based suspension array principle on a Bioplex 2200 System (Biorad Laboratories, 
Cressier, Switzerland). Coefficients of variations, as determined by commercially available 
control materials were 4.5% for total IgA, <2.0% for total IgG, 4.6% for aPL antibodies, and 
3.7% for lupus-antibodies. Measurements were performed at the Labormedizinisches 
Zentrum Dr. Risch, Vaduz, Liechtenstein. 
 
Statistical methods: 
Point estimates of autoantibody levels were described using the mean and the standard 
error of the mean. Differences in autoantibody levels between cohorts were assessed using 
the nonparametric Mann-Whitney test. All P-values were adjusted for multiple hypothesis 
testing using the false discovery rate (FDR) method. Statistical significance was defined at 
the level of FDR <0.05. All analyses were performed using R software, version 3.5.0 (R 
Project for Statistical Computing, Vienna, Austria). Furthermore, we generated hierarchical 
clustering (spearman clustering distance and a complete clustering method) on the median 
centered values of antibody levels. Missing values were replaced with the respective mean 













We collected a total of 64 serum or plasma samples from patients with SARS-CoV-2 
infection (one sample per patient). The median age of all patients was 62 years (interquartile 
range [IQR], 46-74) and 32 (60%) were male. The mCOVID cohort comprised 26 (41%) 
patients with a median age of 57 (IQR, 45-63) years. 9 (35%) of mCOVID patients were 
male. 38 (59%) patients fulfilled the criteria for severe COVID-19. The median age of all 
severely ill patients was 70 (IQR, 58-76) years and, as opposed to mCOVID, they were 
predominantly male (28 [74%]). Of those, the sdCOVID cohort included 14 (22%) patients 
with a median age of 64 (ICR 56-70) years and the scCOVID cohort 24 (38%) patients with a 
median age of 73 (64-80) years. For SARS-CoV-2 diagnosis, 59 (92%) of 64 patients were 
screened by RT-PCR and 7 (11%) patients by serology. 
4/26 (15%) patients in the mCOVID cohort had co-morbidities predisposing to severe 
COVID-19, of which the most frequent was hypertension (3/26 [12%]). In contrast, 26 (93%) 
severely ill patients had at least one co-morbidity, of which the most common were 
hypertension (26 [68%]), cardiovascular disease (25 [66%]) and diabetes mellitus (13/38 
[34%]). Of note, 13 (34%) of patients with severe COVID-19 developed thromboses during 
hospitalization, which did not correlate with d-dimer levels (P=0.48, two-sided t-test). Patient 
characteristics and laboratory values are listed in Table 1.  
 
Antibody results: 
Severely ill COVID-19 patients had significantly higher total IgA titers compared to mCOVID 
patients (sdCOVID, mean 2.94 g/l, SD ±0.46, P=0.01; scCOVID mean 3.04 g/l, SD ±0.19, 
P<0.001), but not higher total IgG (sdCOVID mean 7.69 g/l, SD ±0.55, P=0.09; scCOVID not 
measured). They also had significantly higher anti-Cardiolipin IgA (sdCOVID mean 6.38 











Glycoprotein-1 IgA (sdCOVID mean 8.50 U/ml, SD ±3.86, P<0.001; scCOVID mean 4.71 
U/ml, SD ±2.17, P<0.001), and anti-Cardiolipin IgM (sdCOVID mean 4.01 U/ml, SD ±0.88, 
P=0.003; scCOVID mean 10.35 U/ml, SD ±5.48, P<0.001), as shown in Figure 1. With two 
other aPL antibodies we found a significant difference only in the sdCOVID but not the 
scCOVID cohort: anti-Cardiolipin IgG (sdCOVID mean 8.23 U/ml, SD ±4.02, P=0.02; 
scCOVID mean 2.42, SD ±0.54, P=0.09) and anti-Beta2 Glycoprotein-1 IgG (sdCOVID 
mean 1.57 U/ml, SD ±0.23, P=0.002; scCOVID mean 1.58 U/ml, SD ±0.85, P=0.15). No 
significant difference was found among anti-Beta2 Glycoprotein-1 IgM among the cohorts 
(sdCOVID mean 1.07 U/ml, SD ±0.25, P=0.16; scCOVID mean 2.00 U/ml, SD ±0.72, 
P=0.16), as shown in Figure 2. Hierarchical clustering analysis further demonstrates 
common elevations of antibody titers among patients with mild and severe COVID-19 (see 
Figure 3). We could not detect a correlation between sex and IgA-aPL (anti-Cardiolipin IgA 
male mean 4.46 U/ml, SD±3.70, female mean 3.47 U/ml, SD±3.31, P=0.26; anti-Beta2 
Glycoprotein-1 IgA male mean 3.89 U/ml, SD±8.65, female mean 4.67 U/ml, SD±10.9, 
P=0.76), as shown in Supplementary Figure 1. Also, there was no correlation between age 
and IgA-aPL (anti-Beta2 Glycoprotein-1 IgA R=0.10, P=0.45; anti-Cardiolipin IgA R=0.19, 
P=0.12), presented in Supplementary Figure 2. 
Since APS is commonly triggered by SLE serology screening was performed for all patients, 
as described in the methods section. One patient from the scCOVID cohort had elevated 
anti-La IgG (7.4 U/ml, normal < 1 U/ml) but no other lupus-specific antibodies. None of the 
other patients were positive for any SLE-associated antibodies.  
 
DISCUSSION 
In this study we measured total IgA and IgG, as well as aPL in COVID-19 patients of similar 
age and compared the results of mildly ill with severely ill patients from independent tertiary 











investigation cohort. Our novel finding shows a marked elevation of total IgA that is 
significantly associated with severe COVID-19, which to our knowledge has not been 
reported before. There is no significant association with total IgG. These data support our 
hypothesis, that a strong, IgA-driven immune response possibly emerges from the BALT 
when SARS-CoV-2 affects the deeper respiratory system [16]. In line with literature, about a 
third of severely ill patients developed thromboses [10] that did not correlate with d-dimer 
levels [17, 18]. These thromboses may be explained by an elevation of total IgA and aPL IgA 
antibodies, which we found to be significantly associated with severe illness. This correlation 
could neither be seen for total IgG, nor for aPL IgG antibodies. While an association of 
elevated aPL and severe COVID-19 has been suggested [19], the elevation of total IgA 
together with IgA-aPL when comparing mild and severe COVID-19 is novel and draws the 
missing link between immune response and hypercoagulation, as it strongly suggests 
induction of IgA-dominated APS. APS is most commonly triggered by SLE [12], which was 
excluded in all patients through serological screening [20]. Another potential trigger of APS is 
infection, including pneumonia, that leads to autoimmunity via molecular mimicry [21-23]. In 
the case of COVID-19 such a mechanism may be mediated by pulmonary surfactant, as it is 
rich in phospholipid-binding proteins [24]. Surfactant is produced by type-II pneumocytes, 
which express high levels of ACE-2 receptors and are a primary target of SARS-CoV-2 [8, 
25]. Pneumocyte necrosis leads to surfactant leakage, exposing phospholipid proteins to the 
immune system. It is feasible that peptide commonalities between SARS-CoV-2 and 
surfactant proteins induce APS. Indeed, a high coverage of such peptide commonalities has 
recently been demonstrated by Kanduc D. et al., who found that almost half of the 
immunoreactive epitopes on the spike glycoprotein of SARS-CoV-2 share pentapeptides on 
human surfactant-related proteins [26]. In practice, preliminary results of the COVID-19 
therapy (RECOVERY) trial demonstrate a significant benefit of dexamethasone therapy for 
severely ill patients [27], further suggesting an important role of immune exacerbation in 
COVID-19 related deaths. The effects of aPL could be further enhanced by toll-like receptor-











hypercoagulation [29]. Importantly, these data support a link between IgA and Kawasaki 
disease-like multisystem inflammatory syndrome in children (MIS-C). MIS-C is a novel 
COVID-19 related disease that shows significant overlaps with classical Kawasaki disease 
(KD) but has a later onset and tends to be more severe [30, 31]. Interestingly, classical KD is 
most commonly associated with respiratory viruses [32] and rare severe KD has been shown 
to be associated with organ deposits of IgA-producing plasma cells [33, 34]. This suggests 
that elevated total IgA may have a causal role in MIS-C. 
 
Study limitations: 
Main limitations of the study are its cohort sizes and retrospective design. Furthermore, the 
study does not include longitudinal measurements of antibodies. Due to an inconsistent 
availability of data on past history of thrombosis, pro-inflammatory cytokines and clinical 
outcome, these factors could not be considered. Furthermore, C-reactive protein and d-
dimer levels were only available from the severely ill cohorts. Nevertheless, the inclusion of 
cohorts from independent health care centers, as well as a discovery and a confirmation 
cohort of patients with severe COVID-19 from different hospitals for additional validation are 
major strengths of the study.  
 
In conclusion, we present a novel significant association between severe COVID-19, 
elevated total IgA and IgA-aPL. These findings imply that autoantibodies may hold a causal 
role in severe COVID-19 and its systemic complications. The data strongly suggest that 
COVID-19 is a potent inductor of autoimmunity and recommend further studies with larger 
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Sex - No. (%)    
  Male 9 (35) 8 (57) 20 (83) 
  Female 17 (65) 6 (43) 4 (17) 
Age (median, IQR) - yr 57 (45-63) 64 (56-70) 73 (64-80) 
Comorbiditiesa - No. (%)    
  No 22 (85) 2 (14) 0 (0) 
  Yes 4 (15) 12 (86) 24 (100) 
    Hypertension 3 (12) 10 (71) 16 (67) 
    Cardiovascular disease 0 (0) 6 (43) 19 (79) 
    Cerebrovascular disease 0 (0) 0 (0) 6 (25) 
    Diabetes 1 (4) 5 (36) 8 (33) 
    Liver disease 0 (0) 0 (0) 5 (21) 
    Cancer 0 (0) 0 (0) 9 (38) 
    Kidney disease 0 (0) 5 (36) 7 (29) 
Thromboembolisms, No. (%)    
  Yes 0 (0) 4 (29) 9 (38) 
  No 26 (100) 10 (71) 15 (63) 
Immunosuppression, No. (%)b    
  Yes 0 (0) 5 (36) 5 (21) 
  No 26 (100) 9 (64) 19 (79) 
Laboratory parameters 
(median, IQR) 
   
  C-reactive protein (mg/l)c n/a 228 (95-303) 201 (161-262) 
  Patients contributing to this 
  calculation (n, %) 
0 (0) 14 (100) 24 (100) 





  Patients contributing to this 
  calculation (n, %) 
0 (0) 10 (71) 21 (88) 
 
aComorbidities only consider diagnoses that are known risk factors for developing severe 
COVID-19, as listed. 
bImmunosuppression is defined as systemically administered prednisone ≥7.5mg/day (or 
equivalent), other systemic immunosuppressive drugs, such as calcineurin inhibitors, and 
chemotherapy. 
c,d Maximum values of C-reactive protein and D-dimers during hospitalization. Only patients 
with values available were included (n provided in consecutive line).  
Percentages adding to >100 are due to number rounding. 
Abbreviations: IQR, interquartile range; n/a, not available; mg/l, milligrams per liter; No., 













Figure 1. Antibodies significantly associated with severe COVID-19 in both 
cohorts. Plot titles indicate the respective protein targets and type of 
immunoglobulin. Y-axes reflect measured results and units. X-axes display patient 
counts.  
 
Figure 2. Antibodies with partial or no significant association with severe 
COVID-19. Plot titles indicate the respective protein targets and type of 
immunoglobulin. Y-axes reflect measured results and units. X-axes display patient 
counts. 
 
Figure 3. Hierarchical clustering of antibody levels across patients. The 
heatmap depicts common shifts of antibody levels among patients with mild illness 
and severe COVID-19. Rows show antibodies and columns patients. All antibody 
levels are median centered and are displayed as fold relative compared to the 
median, with higher titers colored red and lower titers blue. For missing results, the 
mean value of the respective antibody/immunoglobulin was used. The scale bar 
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